Stock OTLK OUTLOOK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
8.5 USD 0.00% Intraday chart for Outlook Therapeutics, Inc. +3.79% +7.87%
15/04 Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC CI
15/04 Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Outlook Therapeutics® to Present at the Retina World Congress 2024
AQ
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million
AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
AQ
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC
CI
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC
CI
Corporate Presentation: March 2024
PU
North American Morning Briefing : Stocks Set for -2-
DJ
Outlook Therapeutics Shares Rise After BTIG Upgrade
MT
BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50
MT
Outlook Therapeutics Reports Secondary Share Offering
MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
AQ
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Ease Friday Afternoon
MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell
MT
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
AQ
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
CI
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
AQ
Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OTLK Stock
  4. News Outlook Therapeutics, Inc.